133.04
1.20%
-1.62
Pre-market:
131.84
-1.20
-0.90%
Overview
News
Price History
Option Chain
Why NVO Down?
Discussions
Forecast
Stock Split
Dividend History
Novo Nordisk ADR stock is currently priced at $133.04, with a 24-hour trading volume of 2.88M.
It has seen a -1.20% decreased in the last 24 hours and a +7.77% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $134.1 pivot point. If it approaches the $132.2 support level, significant changes may occur.
Previous Close:
$134.66
Open:
$133.13
24h Volume:
2.88M
Market Cap:
$592.67B
Revenue:
$35.54B
Net Income/Loss:
$12.99B
P/E Ratio:
55.26
EPS:
2.4077
Net Cash Flow:
$7.33B
1W Performance:
+3.40%
1M Performance:
+7.77%
6M Performance:
+33.67%
1Y Performance:
-20.65%
Novo Nordisk ADR Stock (NVO) Company Profile
Name
Novo Nordisk ADR
Sector
Industry
Phone
45 44 44 88 88
Address
Novo Allé, Bagsvaerd
Novo Nordisk ADR Stock (NVO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-12-24 | Initiated | BMO Capital Markets | Outperform |
Jan-23-24 | Initiated | Morgan Stanley | Overweight |
Jan-16-24 | Resumed | UBS | Neutral |
Dec-01-23 | Initiated | Cantor Fitzgerald | Overweight |
Oct-02-23 | Initiated | Argus | Buy |
Jul-14-23 | Initiated | HSBC Securities | Buy |
Jul-15-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jun-28-22 | Downgrade | UBS | Neutral → Sell |
Jun-27-22 | Upgrade | Exane BNP Paribas | Underperform → Neutral |
Jun-07-22 | Upgrade | JP Morgan | Neutral → Overweight |
May-31-22 | Upgrade | Guggenheim | Neutral → Buy |
Apr-25-22 | Upgrade | Cowen | Market Perform → Outperform |
Apr-12-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Mar-16-22 | Upgrade | Deutsche Bank | Hold → Buy |
Jan-25-22 | Downgrade | Liberum | Hold → Sell |
Dec-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
Dec-17-21 | Downgrade | Deutsche Bank | Buy → Hold |
Jan-20-21 | Downgrade | Credit Suisse | Outperform → Neutral |
Jan-15-21 | Initiated | Deutsche Bank | Buy |
Sep-29-20 | Initiated | Berenberg | Hold |
Jul-06-20 | Downgrade | BofA Securities | Buy → Neutral |
May-11-20 | Downgrade | UBS | Buy → Neutral |
May-04-20 | Initiated | Cowen | Market Perform |
Mar-16-20 | Upgrade | BofA/Merrill | Neutral → Buy |
Jan-03-20 | Downgrade | Guggenheim | Buy → Neutral |
Nov-18-19 | Upgrade | Barclays | Equal Weight → Overweight |
Sep-17-19 | Upgrade | Citigroup | Neutral → Buy |
Aug-30-19 | Downgrade | Jefferies | Hold → Underperform |
Jun-20-19 | Downgrade | Deutsche Bank | Buy → Hold |
Jun-11-19 | Upgrade | Barclays | Underweight → Equal Weight |
Apr-29-19 | Upgrade | Credit Suisse | Neutral → Outperform |
Jan-29-19 | Initiated | Exane BNP Paribas | Outperform |
Dec-11-18 | Resumed | Jefferies | Hold |
Oct-09-18 | Initiated | Guggenheim | Buy |
Dec-29-17 | Upgrade | JP Morgan | Underweight → Neutral |
Dec-06-17 | Upgrade | BofA/Merrill | Neutral → Buy |
Dec-01-17 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Sep-25-17 | Downgrade | Exane BNP Paribas | Outperform → Neutral |
Sep-06-17 | Upgrade | BofA/Merrill | Underperform → Neutral |
View All
Novo Nordisk ADR Stock (NVO) Latest News
3 Drug Stocks to Watch on Raised 2024 Earnings & Sales Guidance
Zacks Investment Research
Novo Resources Announces Change of Auditor
GlobeNewswire Inc.
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
Zacks Investment Research
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
Zacks Investment Research
If You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today
The Motley Fool
Eli Lilly (LLY) Settles With Spa Selling Mounjaro, Zepbound Copies
Zacks Investment Research
Novo Nordisk ADR Stock (NVO) Financials Data
Novo Nordisk ADR (NVO) Revenue 2024
NVO reported a revenue (TTM) of $35.54 billion for the quarter ending March 31, 2024, a +34.69% rise year-over-year.
Novo Nordisk ADR (NVO) Net Income 2024
NVO net income (TTM) was $12.99 billion for the quarter ending March 31, 2024, a +51.38% increase year-over-year.
Novo Nordisk ADR (NVO) Cash Flow 2024
NVO recorded a free cash flow (TTM) of $7.33 billion for the quarter ending March 31, 2024, a -22.10% decrease year-over-year.
Novo Nordisk ADR (NVO) Earnings per Share 2024
NVO earnings per share (TTM) was $2.8968 for the quarter ending March 31, 2024, a +52.83% growth year-over-year.
About Novo Nordisk ADR
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk A/S has a research and licensing agreement with DUKE National University Singapore Medical School to develop stem cell-based treatments for chronic heart failure and age-related macular degeneration; and a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S has a collaboration agreement with Embark Biotech ApS for the discovery of novel treatments for obesity and its associated metabolic pathologies. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Cap:
|
Volume (24h):